About ElevateBio
ElevateBio is a company based in Cambridge (United States) founded in 2018 by David Hallal. ElevateBio has raised $1.25 billion across 4 funding rounds from investors including Fidelity Investments, Novo Nordisk and ITOCHU. The company has 309 employees. ElevateBio has completed 1 acquisition, including LifeEDIT. ElevateBio offers products and services including cGMP Manufacturing, Gene Editing Platform, and Process Development. ElevateBio operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Cambridge, United States
- Employees 309
- Founders David Hallal
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website elevate.bio
- Social LinkedIn X
- Legal Name Elevatebio Management, Inc.
- Total Equity Funding$1.25B (USD)
in 4 rounds
- Latest Funding Round$401M (USD), Series D
May 2023
- InvestorsFidelity Investments
& 17 more
- Employee Count309
- Investments & Acquisitions
Products & Services of ElevateBio
ElevateBio offers a comprehensive portfolio of products and services, including cGMP Manufacturing, Gene Editing Platform, and Process Development.
Provides advanced manufacturing for cell and gene therapies
Enables precise gene editing for therapeutic applications
Supports optimization of therapy production processes
Funding Insights of ElevateBio
ElevateBio has successfully raised a total of $1.25B across 4 strategic funding rounds. The most recent funding activity was a Series D round of $401 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.25B
- Total Rounds 4
- Last Round Series D — $401M
- First Round $150M
(May 2019)
- Investors Count 18
All 4 funding rounds of ElevateBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2023 | $401M | Series D | – | Matrix Capital Management | |
| Mar 2021 | $525M | Series C | – | Matrix Capital Management | |
| Mar 2020 | $170M | Series B | – | Invus, Citadel | |
| May 2019 | $150M | Series A | – | MPM Capital |
18 investors in total: 18 institutional.
Investors in ElevateBio
ElevateBio has secured backing from 18 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Novo Nordisk and ITOCHU.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments in technology and startups. | 2016 | visionfund.com | London, United Kingdom | |
- | – | f2-ventures.com | - | |
Venture capital funding is provided by Samsara BioCapital in California. | – | samsaracap.com | Palo Alto, United States | |
Government-backed investments are directed toward healthcare, fintech, and various sectors. | – | edbi.com | Singapore, Singapore | |
Long-term private equity investments in transformational opportunities are pursued. | – | invus.com | New York, United States | |
- | – | vertexventureshc.com | - | |
- | – | matrixcapitalmanagement.com | - | |
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States | |
Operates as an employee-owned hedge fund focused on long/short equity strategies. | 2007 | redmilegroup.com | San Francisco, United States | |
- | – | ecor1cap.com | - |
Investor details for ElevateBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ElevateBio
99 people are tracked at ElevateBio (40 in leadership, 6 in board & advisors, 53 in team); the tracked headcount is 309.
| Name | Role | Group |
|---|---|---|
David Hallal | Co-Founder | Leadership |
Agustin Melian | Chief Development Officer | Leadership |
Doug Chambers | VP, Quality | Leadership |
Cherylene Plewa | VP, Cellular Engineering | Leadership |
Victoria West | Associate Director, People Optimization And Analytics | Leadership |
Kareem Reda | Chief Business Officer | Leadership |
Brian Majors | Vp, Corporate Affairs | Leadership |
Brian Divasta | Director, Computer System Validation | Leadership |
Tedd Elich | Chief Scientific Officer of Life Edit | Leadership |
Missy Kotchey | SVP & Head, People & Culture | Leadership |
Kaylee Strahan | Sr. Director, Human Resources Business Partner | Leadership |
Christian Giotas | Associate Director Engineering Planning | Leadership |
Sophia Kotsalidis | Associate Director Of Process Engineering | Leadership |
Larry Lockwood | Chief Commercial Officer | Leadership |
Aaron Nudelman | SVP & Head, Intellectual Property | Leadership |
Katie Jorgensen | VP & Site Head, BaseCamp | Leadership |
Tess Kitchener | VP, BaseCamp BD Manufacturing | Leadership |
Michael Paglia | CTO, BaseCamp | Leadership |
Nicole Slepsky Partel | Senior Director Human Resources | Leadership |
Adrian Riddell | Vice President, Business Development & Corporate Strategy | Leadership |
79 more people are available in the full profile.
Complete people profiles for ElevateBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ElevateBio
ElevateBio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include LifeEDIT.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Gene therapy therapeutics are developed via genome editing platforms. | lifeeditinc.com | Durham, United States | 2017 | Oct 2021 | •••• |
Complete acquisition details for ElevateBio
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of ElevateBio
4 dated milestones of ElevateBio across 5 years, from founding to its latest funding, stage changes and deals.
- Founded ElevateBio is founded.
- Funding First funding round of $150.0M.
- Acquisition Acquires LifeEDIT.
- Funding Latest funding round, Series D, of $401.0M.
Competitors of ElevateBio
ElevateBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| chimerix.com | 2002 | Durham, United Kingdom | $95.23M | 72 | Antiviral oral therapeutics are developed for infectious diseases and cancers. | |
| cariboubio.com | 2011 | Berkeley, United States | $156.55M | 92 | Provider of cell therapies to treat cancer and hematologic conditions |
Detailed competitors of ElevateBio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ElevateBio
The website of ElevateBio (elevate.bio) receives about 37.6K visits a month and ranks #1,544,839 among all websites worldwide, #2,048 in Biotechnology and Pharmaceuticals.
- Monthly visits37.6K
▲ 78.2% vs previous month
- Unique visitors7.5K
per month
- Global rank#1,544,839
among all websites
- Category rank#2,048
Health · Biotechnology and Pharmaceuticals
- Bounce rate60%
- Pages per visit1.3
- Average visit32 sec
- DevicesDesktop 18% · Mobile 82%
Websites whose visitors overlap most with ElevateBio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| patheon.com | 100% | 89.1K | #488,648 | View details | |
| acadia.com | 100% | 37.8K | #803,210 | View details | |
| springworkstx.com | 99% | 13.6K | #1,818,175 | View details | |
| revmed.com | 94% | 83.2K | #872,423 | View details | |
| fiercebiotech.com | 72% | 858.3K | #81,022 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for ElevateBio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Elevatebio
Complete news archive for ElevateBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ElevateBio
10 companies that operate in the same segment as ElevateBio (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ElevateBio
ElevateBio was founded in 2018 and raised its 1st funding round 1 year after it was founded.
ElevateBio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
ElevateBio is a funded company, having raised a total of $1.25B across 4 funding rounds to date. The company's 1st funding round was a Series A of $150M, raised on May 2019.
ElevateBio has 309 employees.
Provider of transnational research for portfolio of cell and gene therapy. It offers transformative therapy along with other translational research like process development, cGMP manufacturing, clinical development, regulatory affairs, and commercial operations.
ElevateBio's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
ElevateBio offers cGMP Manufacturing, Gene Editing Platform, and Process Development.
ElevateBio has made 1 acquisition, including LifeEDIT.
ElevateBio has 18 investors. Key investors include Fidelity Investments, Novo Nordisk, ITOCHU, Citadel, and SoftBank Vision Fund.
ElevateBio operates through Elevatebio Management, Inc..